Alpha 2.0
Login Register
» Authors » Chantaratsamon Dansirikul

Chantaratsamon Dansirikul

Explore the profile of Chantaratsamon Dansirikul including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 95
Followers 0
Related Specialties
Pharmacology
General Medicine
Biology
Top 10 Co-Authors
Stephen B Duffull
Susan E Tett
Michael Sand
Raymond G Morris
Lien Gheyle
Christian Schultheis
Hanna E Silber
Fabian Muller
Jasmin Link
Roman Laszlo
Published In
Ther Drug Monit
J Pharmacokinet Pharmacodyn
Eur J Clin Pharmacol
Comput Biol Med
J Clin Pharmacol
Affiliations
Soon will be listed here.
Recent Articles
1.
The effect of BI 409306 on heart rate in healthy volunteers: a randomised, double-blind, placebo-controlled, crossover study
Muller F, Sand M, Wunderlich G, Link J, Schultheis C, Dansirikul C, et al.
Eur J Clin Pharmacol . 2022 Jan; 78(5):801-812. PMID: 35089373
Purpose: The potent, selective phosphodiesterase-9A inhibitor BI 409306 may be beneficial for patients with attenuated psychosis syndrome and could prevent relapse in patients with schizophrenia. Transient BI 409306-dependent increases in...
2.
A phase I, randomized, proof-of-clinical-mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers
Boland K, Moschetti V, Dansirikul C, Pichereau S, Gheyle L, Runge F, et al.
Hum Psychopharmacol . 2017 Jan; 32(1). PMID: 28120486
Objective: Cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase (PDE) inhibitors are hypothesized to improve cognition in schizophrenia and Alzheimer disease by increasing cGMP levels in certain brain regions. This phase I, randomized,...
3.
A semi-physiological model of amyloid-β biosynthesis and clearance in human cerebrospinal fluid: a tool for alzheimer's disease research and drug development
Haug K, Staab A, Dansirikul C, Lehr T
J Clin Pharmacol . 2013 May; 53(7):691-8. PMID: 23712554
Stable isotope labeling kinetics (SILK) was successfully applied to quantify endogenous amyloid-β (Aβ) metabolism in human cerebrospinal fluid (CSF). A semi-physiological model describing Aβ biosynthesis and degradation in human CSF...
4.
Approaches to handling pharmacodynamic baseline responses
Dansirikul C, Silber H, Karlsson M
J Pharmacokinet Pharmacodyn . 2008 May; 35(3):269-83. PMID: 18446428
A few approaches for handling baseline responses are available for use in pharmacokinetic (PK)-pharmacodynamic (PD) analysis. They include: (method 1-B1) estimation of the typical value and interindividual variability (IIV) of...
5.
A Bayesian approach for population pharmacokinetic modelling of sirolimus
Dansirikul C, Morris R, Tett S, Duffull S
Br J Clin Pharmacol . 2006 Sep; 62(4):420-34. PMID: 16995863
Aims: To explore a Bayesian approach for the pharmacokinetic analysis of sirolimus concentration data arising from therapeutic drug monitoring (poorly informative concentration-time point design), and to explore possible covariate relationships...
6.
Estimation of pharmacokinetic parameters from non-compartmental variables using Microsoft Excel
Dansirikul C, Choi M, Duffull S
Comput Biol Med . 2005 Mar; 35(5):389-403. PMID: 15767115
This study was conducted to develop a method, termed 'back analysis (BA)', for converting non-compartmental variables to compartment model dependent pharmacokinetic parameters for both one- and two-compartment models. A Microsoft...
7.
Sampling times for monitoring tacrolimus in stable adult liver transplant recipients
Dansirikul C, Staatz C, Duffull S, Taylor P, Lynch S, Tett S
Ther Drug Monit . 2004 Dec; 26(6):593-9. PMID: 15570182
The aim of this study was to determine the most informative sampling time(s) providing a precise prediction of tacrolimus area under the concentration-time curve (AUC). Fifty-four concentration-time profiles of tacrolimus...